The National Institute of Influential Diseases (Director Jang Hee-chang) under the Korea National Institute of Health (Director Kwon Joon-wook) announced the results of the efficacy evaluation of treatments such as COVID-19 PO treatments, that is, Paxlovid and Lagevrio. Compared to the existing delta mutant virus, these drugs have maintained their effectiveness in suppressing virus proliferation, so they are not affected by omicron submutation. It was decided to prepare treatment guidelines through research on chronic aftereffects in the future.

First, the National Institute of Influential Diseases evaluated the efficacy of three domestic COVID-19 antiviral drugs (Paxlovid, Lagevrio, Remdesivir) through